Recent Updates — NONOF

Martin Holst Lange, Executive Vice President and Chief Scientific Officer, sold 12,000 Novo Nordisk B shares on November 4, 2026, at a price of DKK 285.00 per share, resulting in an aggregate transaction value of approximately DKK 3,420,000. The sale was reported to the company and published pursuant to Article 19 of Regulation No. 596/2014 on market abuse. Novo Nordisk is a global healthcare company that develops treatments for diabetes, obesity, and other chronic diseases.

Novo Nordisk raised its full-year adjusted sales and operating profit growth expectations to -2% to +2% at constant exchange rates, citing continued momentum in GLP-1 products. Third-quarter adjusted operating profit increased 27% at CER to DKK 31,720 million, driven by obesity volume growth and a favorable comparison base after prior-year transformation costs. However, reported operating profit fell 9% at CER due to DKK 8.7 billion in non-cash impairment charges related to the ziltivekimab program and manufacturing network right-sizing. The company also highlighted strong commercial uptake of Wegovy pill launches across eight markets globally. Novo Nordisk A/S is a global healthcare company focused on discovering, developing, and delivering innovative medicines for patients with serious chronic diseases.

Novo Nordisk provided a routine progress report on its share repurchase programme, detailing transactions executed between October 26 and November 2, 2026. The company bought an additional 1,440,000 B shares at an average price of DKK 263.59, adding approximately DKK 387 million to the total spend. Since February 4, 2026, Novo Nordisk has repurchased a cumulative 41,714,179 B shares for DKK 11.56 billion, holding 55,754,876 treasury shares representing 1.2% of capital. The company aims to spend up to DKK 15 billion over the 12-month period ending February 3, 2027. Novo Nordisk is a global healthcare company developing treatments for diabetes, obesity, and other chronic diseases.

Novo Nordisk has executed additional share repurchases as part of its broader DKK 15 billion programme initiated in February 2026. Since October 19, the company bought approximately 1.2 million B shares for roughly DKK 314 million at prices between DKK 257 and DKK 263 per share. As of late October, total repurchases under the current cycle reached DKK 11.2 billion, representing about 90% of the authorised limit. Novo Nordisk is a global healthcare company developing treatments for diabetes, obesity, and other chronic diseases.

Novo Nordisk reported share repurchase transactions executed between October 12 and October 16, 2026. The company bought a total of 985,000 B shares at an average price of approximately DKK 257 per share, totaling roughly DKK 317 million in transaction value. Since the start of the program on February 4, 2026, Novo Nordisk has repurchased 39,074,179 B shares for a cumulative total of DKK 10.88 billion. The company holds 53,114,876 treasury shares, representing 1.2% of its share capital. Novo Nordisk is a global healthcare company developing treatments and support to help millions of people make progress they can see, feel and sustain now and in the future.